ATE500276T1 - Humanisierte col-1-antikörper mit substituierten resten am gerüst, und deren anwendung - Google Patents

Humanisierte col-1-antikörper mit substituierten resten am gerüst, und deren anwendung

Info

Publication number
ATE500276T1
ATE500276T1 AT05855920T AT05855920T ATE500276T1 AT E500276 T1 ATE500276 T1 AT E500276T1 AT 05855920 T AT05855920 T AT 05855920T AT 05855920 T AT05855920 T AT 05855920T AT E500276 T1 ATE500276 T1 AT E500276T1
Authority
AT
Austria
Prior art keywords
humanized col
antibodies
disclosed
col
residies
Prior art date
Application number
AT05855920T
Other languages
English (en)
Inventor
Syed Kashmiri
Jeffrey Schlom
Eduardo Padlan
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE500276T1 publication Critical patent/ATE500276T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT05855920T 2004-12-30 2005-12-30 Humanisierte col-1-antikörper mit substituierten resten am gerüst, und deren anwendung ATE500276T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64067204P 2004-12-30 2004-12-30
PCT/US2005/047431 WO2006074071A1 (en) 2004-12-30 2005-12-30 Framework residue substituted humanized col-1 antibodies and their use

Publications (1)

Publication Number Publication Date
ATE500276T1 true ATE500276T1 (de) 2011-03-15

Family

ID=36216923

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05855920T ATE500276T1 (de) 2004-12-30 2005-12-30 Humanisierte col-1-antikörper mit substituierten resten am gerüst, und deren anwendung

Country Status (7)

Country Link
US (2) US7855276B2 (de)
EP (1) EP1833850B9 (de)
AT (1) ATE500276T1 (de)
AU (1) AU2005322869B2 (de)
CA (1) CA2593693A1 (de)
DE (1) DE602005026706D1 (de)
WO (1) WO2006074071A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5836125B2 (ja) 2008-10-16 2015-12-24 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 高分子量メラノーマ関連抗原に対する完全ヒト抗体およびその使用
GB0914691D0 (en) 2009-08-21 2009-09-30 Lonza Biologics Plc Immunoglobulin variants
CN103403026B (zh) 2009-09-25 2016-05-11 美国政府(由卫生和人类服务部的部长所代表) Hiv-1中和抗体及其用途
EP2582727B8 (de) 2010-06-16 2017-04-19 University of Pittsburgh- Of the Commonwealth System of Higher Education Antikörper zu endoplasmin und deren verwendung
EP2646054A4 (de) 2010-12-02 2015-03-04 Univ Pittsburgh Verfahren zur behandlung eines tumors mithilfe eines antikörpers zur spezifischen bindung an grp94
WO2013086533A1 (en) 2011-12-08 2013-06-13 The United States Of America, As Represented By The Secretary Department Of Health & Human Services Neutralizing antibodies to hiv-1 and their use
ES2766762T3 (es) 2013-03-13 2020-06-15 Prothena Biosciences Ltd Inmunoterapia contra Tau
AU2017259039B2 (en) 2016-05-02 2024-05-09 Prothena Biosciences Limited Antibodies recognizing tau
US10889638B2 (en) 2016-05-02 2021-01-12 Prothena Biosciences Limited Antibodies recognizing tau
ES2933491T3 (es) 2016-05-02 2023-02-09 Prothena Biosciences Ltd Inmunoterapia tau
AU2018263935B2 (en) * 2017-05-02 2024-09-26 Prothena Biosciences Limited Antibodies recognizing tau
TWI859197B (zh) 2019-03-03 2024-10-21 愛爾蘭商普羅帝納生物科學公司 識別ｔａｕ之抗體
CN113393899A (zh) * 2021-05-26 2021-09-14 江苏普瑞康生物医药科技有限公司 基于动态规划的抗体人源化的方法与装置

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851526A (en) * 1985-04-19 1998-12-22 Ludwig Institute For Cancer Research Methods of treating colon cancer utilizing tumor-specific antibodies
GB8800077D0 (en) * 1988-01-05 1988-02-10 Ciba Geigy Ag Novel chimeric antibodies
US5472693A (en) * 1993-02-16 1995-12-05 The Dow Chemical Company Family of anti-carcinoembryonic antigen chimeric antibodies
US6417337B1 (en) * 1996-10-31 2002-07-09 The Dow Chemical Company High affinity humanized anti-CEA monoclonal antibodies
JP4803879B2 (ja) 1998-10-31 2011-10-26 アメリカ合衆国 ヒト化抗−癌腫モノクローナル抗体ｃｃ４９
US7321026B2 (en) 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
CA2491864C (en) 2001-07-12 2012-09-11 Jefferson Foote Super humanized antibodies
WO2004022717A2 (en) 2002-09-05 2004-03-18 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Minimally immunogenic variants of humanized col-1 antibody against carcinoembryonic antigen
EP2368578A1 (de) * 2003-01-09 2011-09-28 Macrogenics, Inc. Identifizierung und Herstellung von Antikörpern mit abweichenden FC-Regionen und Anwendungsverfahren dafür

Also Published As

Publication number Publication date
EP1833850B1 (de) 2011-03-02
US20110053264A1 (en) 2011-03-03
DE602005026706D1 (de) 2011-04-14
AU2005322869A1 (en) 2006-07-13
WO2006074071A8 (en) 2006-09-14
AU2005322869B2 (en) 2011-05-12
WO2006074071A1 (en) 2006-07-13
US7855276B2 (en) 2010-12-21
CA2593693A1 (en) 2006-07-13
EP1833850B9 (de) 2011-05-18
US8828717B2 (en) 2014-09-09
EP1833850A1 (de) 2007-09-19
US20080274055A1 (en) 2008-11-06

Similar Documents

Publication Publication Date Title
ATE500276T1 (de) Humanisierte col-1-antikörper mit substituierten resten am gerüst, und deren anwendung
DE60333732D1 (de) Internalisierung von anti cd74 monoklonalen antikörpern und deren verwendungen
WO2005112564A3 (en) Germline and sequence variants of humanized antibodies and methods of making and using them
JP2017508475A5 (de)
ATE492563T1 (de) Vollständige humane monoklonale antikörper gegen il-13
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
TR200807263A2 (tr) IgG'nin FcRn'ye bağlanmasını bloke eden peptidler
DE60239454D1 (de) Rekombinanter, tumorspezifischer antikörper und dessen verwendung
EA201590631A1 (ru) Антигенсвязывающие белки, способные связывать тимусный стромальный лимфопоэтин
NO20090462L (no) Anti-NKG2A-antistoffer og anvendelser derav
NZ592054A (en) Dengue virus neutralizing antibodies and uses thereof
WO2007092939A3 (en) Antigenic gm-csf peptides and antibodies to gm-csf
MX2009012493A (es) Metodos de humanizacion de anticuerpo de conejo novedosos y anticuerpos de conejo humanizados.
SG170793A1 (en) Anti-mn antibodies and methods of using same
WO2004083249A3 (en) Antibodies against human il-21 receptor and uses therefor
ATE373719T1 (de) Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung
DE60334364D1 (de) Behandlungsverfahren unter verwendung von anti-cd22-antikörpern
DE60329823D1 (de) Antikörper mit t-zell-rezeptor-artiger spezifität, aber höherer affinität und seine verwendung zum nachweis und zur behandlung von krebs, virusinfektionen und autoimmunkrankheiten
UA105760C2 (uk) Антитіло проти bst2
IN2012DN05101A (de)
WO2004035742A3 (en) Sets of digital antibodies directed against short epitopes, and methods using same
EA200700876A1 (ru) Агенты, специфически связывающие ангиопоэтин-2
WO2021226289A3 (en) Compositions and methods for tcr reprogramming using cd70 specific fusion proteins
MX2024004620A (es) Receptores de antigeno quimerico anti-steap2 y usos de los mismos.
EP2192132A3 (de) Anti-il-20-, Anti-il-22- und Anti-il-22ra-Antikörper und Bindungspartner sowie Verwendungsverfahren bei Entzündungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties